Kenvue Inc. $KVUE Shares Bought by Tidal Investments LLC

Tidal Investments LLC grew its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 14.0% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 549,380 shares of the company’s stock after purchasing an additional 67,537 shares during the period. Tidal Investments LLC’s holdings in Kenvue were worth $10,499,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Elyxium Wealth LLC bought a new stake in shares of Kenvue in the 4th quarter worth approximately $26,000. Johnson Financial Group Inc. bought a new stake in Kenvue during the second quarter worth approximately $26,000. MV Capital Management Inc. acquired a new position in Kenvue in the fourth quarter worth approximately $28,000. CoreCap Advisors LLC grew its position in Kenvue by 64.9% in the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after buying an additional 591 shares during the last quarter. Finally, Reflection Asset Management bought a new position in shares of Kenvue in the fourth quarter valued at $32,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Trading Down 0.3%

NYSE KVUE opened at $17.73 on Friday. The firm’s 50 day moving average price is $19.05 and its two-hundred day moving average price is $18.24. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.71 and a current ratio of 1.01. Kenvue Inc. has a twelve month low of $14.02 and a twelve month high of $20.13. The stock has a market cap of $34.06 billion, a price-to-earnings ratio of 20.39, a PEG ratio of 1.59 and a beta of 0.46.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The business had revenue of $3.96 billion during the quarter, compared to analysts’ expectations of $3.97 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. Kenvue’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.29 EPS. Equities analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 2nd. Investors of record on Monday, September 21st will be paid a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 4.7%. The ex-dividend date of this dividend is Monday, September 21st. Kenvue’s dividend payout ratio is currently 96.55%.

Wall Street Analysts Forecast Growth

KVUE has been the subject of a number of recent research reports. Barclays increased their price objective on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 21st. Wall Street Zen lowered Kenvue from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings raised Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 15th. UBS Group dropped their price target on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 11th. Finally, Zacks Research downgraded Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Three analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $19.27.

Kenvue Profile

Kenvue Inc is a global consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, essential health products, and baby and family care.

The company’s brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; Listerine in oral care; and Johnson’s and Band-Aid in baby care and essential health.